Sarah Twinney

Sarah Twinney is an accomplished research scientist currently working at Bolden Therapeutics, focusing on developing antisense oligonucleotide therapy for Alzheimer's Disease. With a Master of Science in Biotechnology from Brown University, Sarah has experience in designing and executing in vitro experiments, optimizing laboratory techniques, and managing multiple projects simultaneously. Previous roles include a Research Co-Op at Brown University, where Sarah utilized Drosophila models to study ALS, and positions in marketing and product management at Start Line Brewing and Medline Industries, respectively, where Sarah drove growth and implemented effective marketing strategies. Sarah's leadership and organizational skills have been demonstrated through various roles, including serving as lab manager and vice president of membership in a professional business fraternity.